| Identification | Back Directory | [Name]
Benzamide, N-hydroxy-4-[[[[(2-methoxyphenyl)amino]carbonyl]amino]methyl]- | [CAS]
1454902-97-6 | [Synonyms]
Elevenostat
N-hydroxy-4-((3-(2-methoxyphenyl)ureido)methyl)benzamide
Benzamide, N-hydroxy-4-[[[[(2-methoxyphenyl)amino]carbonyl]amino]methyl]- | [Molecular Formula]
C16H17N3O4 | [MOL File]
1454902-97-6.mol | [Molecular Weight]
315.32 |
| Chemical Properties | Back Directory | [density ]
1.328±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : 250 mg/mL (792.85 mM; Need ultrasonic) | [form ]
Solid | [pka]
8.92±0.10(Predicted) | [color ]
Off-white to pink |
| Hazard Information | Back Directory | [Uses]
Elevenostat (JB3-22) is a selective HDAC11 inhibitor with an IC50 of 0.235 μM. Elevenostat can induce apoptosis of multiple myeloma cells and has anti-tumor effect. In addition, Elevenostat inhibits the maturation of mouse oocytes[1][2]. | [Biological Activity]
Elevenostat (JB3-22) is a selective HDAC11 inhibitor (IC50=0.235 μM). Anti-multiple myeloma (MM) activity[1]. | [in vivo]
Elevenostat (1-10 mg/kg; intraperitoneal injection; 0-4 weeks) has an anti-tumor effect in a mouse model of multiple myeloma[3]. | Animal Model: | 5TGM1/C57BL/KaLwRij mouse multiple myeloma model[3] | | Dosage: | 1 mg/kg and 10 mg/kg | | Administration: | Intraperitoneal injection (i.p.); once daily for the first 10 days and every alternate day for the rest of the treatment period until mice reached disease endpoint.
| | Result: | Effectively inhibited tumor growth.
Decrease serum IgG2b level.
Significantly prolonged the survival period of tumor-bearing mice.
Was well-tolerated at these doses and dosing frequencies, supported by lack of changes in body weight.
|
| [IC 50]
HDAC11: 0.235 μM (IC50); Caspase-3 | [storage]
Store at -20°C | [References]
[1]. Huang J, et al. Histone/protein deacetylase 11 targeting promotes Foxp3+ Treg function. Sci Rep. 2017;7(1):8626. Published 2017 Aug 17.
[2]. Mostofa A, et al. Plasma cell dependence on histone/protein deacetylase 11 reveals a therapeutic target in multiple myeloma. JCI Insight. 2021;6(24):e151713. Published 2021 Dec 22. |
|
| Company Name: |
InvivoChem
|
| Tel: |
13549236410 |
| Website: |
https://www.invivochem.cn/ |
| Company Name: |
Abcam Limited
|
| Tel: |
021-2070050 400921018 |
| Website: |
www.abcam.cn |
|